Biohaven Ltd. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Biohaven initiated a pivotal Phase 3 study for BHV-1300 in Graves' disease (approximately 300 patients; mean ≥80% reduction in pathogenic autoantibodies by week 12 in Phase 1b) and plans to initiate Phase 3 for BHV-1400 in IgA Nephropathy in 2H 2026 (mean ≥60% reduction in pathogenic Gd-IgA1 within 48 hours in Phase 1b). The company also reported Phase 2/3 opakalim epilepsy data on track for 2H 2026 readout, new BHV-1530 oncology data expected at ESMO in October 2026, and a clinical supply agreement with Regeneron for combination studies. Cash, equivalents, and marketable securities totaled $270.5M as of June 30, 2026.
Why this rating
Phase 3 initiation in two major programs represents material clinical progression for ~$1B market-cap biotech; $270.5M cash supports 18+ months runway at current burn; multiple near-term catalysts reduce near-term dilution risk.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.